CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pernix Therapeutics Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Suite 201
Phone: (862) 260-8457p:862 260-8457 Morristown, NJ  07960-7101  United States Fax: (862) 260-8752f:862 260-8752
This company's Plan of Liquidation went into effect on 6/24/2019
This company ceased filing statements with the SEC on 9/25/2019.
This entity represents the bankrupt estate of the former business (assets) of Pernix Therapeutics Holdings, Inc. that was not sold to Currax Holdings LLC on 4/30/2019.
This company is no longer actively traded on any major stock exchange.
Business Summary
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201812/31/2017YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer John A.Sedor 73 7/26/2016 3/13/2014
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Controller GlennWhaley 50 11/23/2018 11/29/2017
Lead Independent Director John R.Leone 70 2/6/2018 11/15/2017

Subsidiaries
Business Name Address City State/Province Country
Cypress Pharmaceuticals, Inc. 10 North Park Place Morristown NJ United States
Pernix Sleep, Inc. 10 North Park Place Morristown NJ United States
Pernix Therapeutics, LLC 10 North Park Place Morristown NJ United States
Macoven Pharmaceuticals, LLC 10 North Park Place, Suite 201 Morristown NJ United States
Pernix Manufacturing, LLC 10 North Park Place Morristown, NJ United States

Business Names
Business Name
Cypress Pharmaceutical, Inc.
Gaine, Inc.
GTAP
16 additional Business Names available in full report.

General Information
Number of Employees: 171 (As of 12/31/2017)
Outstanding Shares: 14,505,848 (As of 11/6/2018)
Shareholders: 119
Stock Exchange: OTC
Federal Tax Id: 330724736
Fax Number: (862) 260-8752


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023